To date, four preclinical studies have used CAART cell therapy for autoimmune disorders: specifically for the treatment of pemphigus vulgaris [26], MuSK autoantibody-positive myasthenia gravis [27], NMDAR encephalitis [28], and experimental autoimmune encephalomyelitis (EAE) [29]. The gene discussed is MUSK; the disease is pemphigus vulgaris.